Company news
Endonovo Therapeutics, Inc. (OTC:ENDV) news
Endonovo Therapeutics, Inc. news releases on 6ix. Latest, Dec 4, 2023: Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse…
Press releases & updates
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
December 3, 2023
Endonovo's SofPulse® Secures Taiwan FDA Approval
October 11, 2023
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
August 21, 2023
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
August 7, 2023
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
June 21, 2023
Endonovo Pending Agreement to Develop Telehealth Division
June 6, 2023
Endonovo Launches SofPulse® into the Veterans Administration
May 1, 2023
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
April 24, 2023
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
April 12, 2023
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
April 9, 2023
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
March 28, 2023
Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
March 22, 2023
Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery
March 14, 2023
Endonovo Announces Distribution Agreement with Academy Medical
March 5, 2023
Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg
February 28, 2023
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
January 31, 2023
Endonovo Partners with International Distributor for SofPulse® Line
January 26, 2023
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
January 19, 2023
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
January 9, 2023
Endonovo Targets Dept. of Defense, VA & Federal Contracts
January 3, 2023
Endonovo Announces Advancement of International “Go to Market” Initiative
December 19, 2022
Endonovo Announces Plans for Spin-off of Medical IP and Assets
December 15, 2022
Endonovo Launches Telehealth Initiative
December 13, 2022
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
November 30, 2022
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
November 17, 2022
Endonovo Therapeutics Issues Corporate Update
November 7, 2022
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
September 27, 2022
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
July 28, 2022
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
July 21, 2022
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
June 9, 2022
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
April 25, 2022
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
March 1, 2022
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
February 16, 2022
Endonovo Therapeutics Issues Shareholder Update
October 12, 2021
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
October 8, 2020
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
September 9, 2020
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
August 20, 2020
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
July 27, 2020
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
July 21, 2020
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
June 15, 2020
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
June 1, 2020
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
May 26, 2020
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
May 4, 2020
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
April 16, 2020
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
March 25, 2020
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
March 16, 2020
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
March 2, 2020
Endonovo Therapeutics Introduces Support of SofPulse® With A New Ancillary Multi-Use Patient Brace From Protex
February 24, 2020